Palonosetron for the treatment of chemotherapy-induced nausea and vomiting (Q38260952)

1 September 2017

1 reference

title

Palonosetron for the treatment of chemotherapy-induced nausea and vomiting (English)

1 reference

1 September 2017

1 reference

Rudolph M Navari

1 reference

1 September 2017

language of work or name

English

0 references

publication date

17 October 2014

1 reference

Expert Opinion on Pharmacotherapy

1 September 2017

published in

1 reference

1 September 2017

1 reference

1 September 2017

1 reference

1 September 2017

page(s)

2599-2608

1 reference

Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment

1 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972366

Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972366

Management of chemotherapy-induced nausea and vomiting : focus on newer agents and new uses for older agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972366

Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972366

The current status of the use of palonosetron

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972366

Aprepitant: a review of its use in the prevention of nausea and vomiting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972366

Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972366

Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972366

Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972366

Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972366

Antiemetics: American Society of Clinical Oncology clinical practice guideline update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972366

Neurons in the nucleus of the solitary tract mediating inputs from emetic vagal afferents and the area postrema to the pattern generator for the emetic act in dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972366

Tropisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972366

Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972366

Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972366

Delayed emesis: moderately emetogenic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972366

Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972366

5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972366

Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972366

Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972366

Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972366

Pharmacological characterization of RS 25259-197, a novel and selective 5-HT3 receptor antagonist, in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972366

Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972366

Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972366

Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972366

Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972366

Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemothe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972366

Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972366

Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972366

Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972366

Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972366

Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972366

Pneumatosis intestinalis in children with acute lymphoblastic leukemia and acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972366

A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972366

A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972366

Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972366

Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972366

Radioreceptor binding profile of the atypical antipsychotic olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972366

Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972366

Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972366

Palonosetron to prevent nausea and vomiting in children undergoing BMT: efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972366

Palonosetron in prevention of nausea and vomiting after highly emetogenic chemotherapy before haematopoietic stem cell transplantation-single center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972366

Palonosetron and dexamethasone for prevention of nausea and vomiting in patients receiving high-dose chemotherapy with auto-SCT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972366

10.1517/14656566.2014.972366

21 January 2018

Identifiers

DOI

1 reference

1 September 2017

1 reference